A High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor Development

The sequence of the human genome

Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909 · see citing works

The Sequence of the Human Genome

Venter, J., Adams, M., Myers, E., Li, P. W., Mural, R., Sutton, G., Smith, H., Yandell, M., Evans, C., Holt, R., et al. (2001) · Science · doi:10.1373/clinchem.2014.237016 · Cited by 6,779 · see citing works

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

Mdm2 promotes the rapid degradation of p53

Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · see citing works

Regulation of p53 stability by Mdm2

Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · see citing works

DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2

Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · see citing works

Tumor spectrum analysis in p53-mutant mice

Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051 · see citing works

Amplification of a gene encoding a p53-associated protein in human sarcomas

Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949 · see citing works

A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans

Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265 · see citing works

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome

Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · see citing works

DNA damage induces phosphorylation of the amino terminus of p53

Siliciano, J. D., Canman, C. E., Taya, Y., Sakaguchi, K., Appella, E., & Kastan, M. B. (1997) · Genes & Development · doi:10.1101/gad.11.24.3471 · Cited by 818 · see citing works

MDM2, an introduction.

Iwakuma, T., & Lozano, G. (2003) · PubMed · Cited by 390 · see citing works

Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice

Liu, G., Parant, J. M., Lang, G., Chau, P., Chavez-Reyes, A., El-Naggar, A. K., Multani, A., Chang, S., & Lozano, G. (2004) · Nature Genetics · doi:10.1038/ng1282 · Cited by 325 · see citing works

MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner

Bond, G. L., Hirshfield, K. M., Kirchhoff, T., Alexe, G., Bond, E. E., Robins, H., Bartel, F., Taubert, H., Wuerl, P., Hait, W., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0180 · Cited by 287 · see citing works

p53 mutation heterogeneity in cancer

Soussi, T., & Lozano, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.190 · Cited by 275 · see citing works

Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53.

Lundgren, K., Montes de Oca Luna, R., McNeill, Y. B., Emerick, E. P., Spencer, B., Barfield, C. R., Lozano, G., Rosenberg, M. P., & Finlay, C. A. (1997) · Genes & Development · doi:10.1101/gad.11.6.714 · Cited by 235 · see citing works

<i>mdm2</i> Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation

Mendrysa, S. M., McElwee, M. K., Michalowski, J., O'Leary, K. A., Young, K. M., & Perry, M. E. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.2.462-473.2003 · Cited by 234 · see citing works

Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome

Bougeard, G., Baert-Desurmont, S., Tournier, I., Vasseur, S., Martin, C., Brugières, L., Chompret, A., Paillerets, B. B., Stoppa‐Lyonnet, D., Bonaïti‐Pellié, C., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2005.037952 · Cited by 216 · see citing works

Tumor suppression and normal aging in mice with constitutively high p53 activity

Mendrysa, S. M., O'Leary, K. A., McElwee, M. K., Michalowski, J., Eisenman, R. N., Powell, D. A., & Perry, M. E. (2006) · Genes &amp; Development · doi:10.1101/gad.1378506 · Cited by 210 · see citing works

20 years studying p53 functions in genetically engineered mice

Donehower, L. A., & Lozano, G. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2731 · Cited by 193 · see citing works

A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans

Bond, G. L., & Levine, A. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210199 · Cited by 186 · see citing works

Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer Cells

Jackson, J. G., White, M. F., & Yee, D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.16.9994 · Cited by 173 · see citing works

Younger Age of Cancer Initiation Is Associated with Shorter Telomere Length in Li-Fraumeni Syndrome

Tabori, U. Y., Nanda, S., Druker, H. A., Lees, J., & Malkin, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3682 · Cited by 149 · see citing works

Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis

Alt, J. R., Greiner, T. C., Cleveland, J. L., & Eischen, C. M. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg133 · Cited by 129 · see citing works

Association Between MDM2–SNP309 and Age at Colorectal Cancer Diagnosis According to p53 Mutation Status

Menin, C., Scaini, M. C., Salvo, G. L. D., Biscuola, M., Quaggio, M., Esposito, G., Belluco, C., Montagna, M., Agata, S., D’Andrea, E., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj054 · Cited by 121 · see citing works

Haploinsufficiency of <i>Mdm2</i> and <i>Mdm4</i> in Tumorigenesis and Development

Terzian, T., Wang, Y., Van Pelt, C. S., Box, N. F., Travis, E. L., & Lozano, G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00555-06 · Cited by 116 · see citing works

The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li–Fraumeni syndrome and related phenotypes

Ruijs, M., Schmidt, M. K., Nevanlinna, H. A., Tommiska, J., Aittomäki, K., Pruntel, R., Verhoef, S., & Veer, L. J. V. (2006) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201715 · Cited by 103 · see citing works

MDM2 Promoter SNP309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C

Dharel, N., Kato, N., Muroyama, R., Moriyama, M., Shao, R., Kawabe, T., & Omata, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0111 · Cited by 92 · see citing works

MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility

Ellis, N. A., Huo, D., Yildiz, O., Worrillow, L. J., Banerjee, M., Beau, M. M. L., Larson, R. A., Allan, J. M., & Onel, K. (2008) · Blood · doi:10.1182/blood-2007-11-126508 · Cited by 86 · see citing works

High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas

Valentin-Vega, Y. A., Barboza, J., Chau, G. P., El‐Naggar, A. K., & Lozano, G. (2007) · Human Pathology · doi:10.1016/j.humpath.2007.03.005 · Cited by 85 · see citing works

Do MDM2 SNP309 and TP53 R72P Interact in Breast Cancer Susceptibility? A Large Pooled Series from the Breast Cancer Association Consortium

Schmidt, M. K., Reincke, S., Broeks, A., Braaf, L. M., Hogervorst, F. B. L., Tollenaar, R. A. �. �., Johnson, N., Fletcher, O., Peto, J., Tommiska, J., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0738 · Cited by 79 · see citing works

TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li–Fraumeni syndrome: impact on age at first diagnosis

Marcel, V., Palmero, E. I., Falagan-Lotsch, P., Martel‐Planche, G., Ashton‐Prolla, P., Olivier, M., Brentani, H., Hainaut, P. L., & Achatz, M. I. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2009.066704 · Cited by 78 · see citing works

Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis

Economopoulos, K. P., & Sergentanis, T. Ν. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0467-1 · Cited by 73 · see citing works

p53-dependent senescence delays Eμ-myc-induced B-cell lymphomagenesis

Post, S. M., Quintás‐Cardama, A., Terzian, T., Smith, C., Eischen, C. M., & Lozano, G. (2009) · Oncogene · doi:10.1038/onc.2009.423 · Cited by 58 · see citing works

A comprehensive study of p53 transcriptional activity in thymus and spleen of γ irradiated mouse: High sensitivity of genes involved in the two main apoptotic pathways

Alvarez, S., Drané, P., Meiller, A., Bras, M., Chambon, V., Bouvard, V., & May, E. (2006) · International Journal of Radiation Biology · doi:10.1080/09553000600949624 · Cited by 47 · see citing works

MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish–Ashkenazi descent

Yarden, R. I., Friedman, E., Metsuyanim, S., Olender, T., Ben‐Asher, E., & Papa, M. Z. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9797-z · Cited by 47 · see citing works

Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers

Copson, E., White, H., Blaydes, J., Robinson, D., Johnson, P. W. M., & Eccles, D. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-80 · Cited by 44 · see citing works

MDM2SNP309 Does Not Associate with Elevated MDM2 Protein Expression or Breast Cancer Risk

Krekac, D., Hrazdilová, K., Knoflíčková, D., Hrstka, R., Müller, P., Nenutil, R., & Vojtěšek, B. (2008) · Oncology · doi:10.1159/000139135 · Cited by 27 · see citing works

Associations of MDM2 SNP309, Transcriptional Activity, mRNA Expression, and Survival in Stage I Non-Small-Cell Lung Cancer Patients with Wild-Type p53 Tumors

Chien, W.-P., Wong, R., Cheng, Y., Chen, C., & Lee, H. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0853-2 · Cited by 24 · see citing works

MDM2 SNP309 Associates With Accelerated Pancreatic Adenocarcinoma Formation

Grochola, L. F., Müller, T. H., Bond, G. L., Taubert, H. W., Udelnow, A., & Würl, P. (2009) · Pancreas · doi:10.1097/mpa.0b013e3181b9f105 · Cited by 22 · see citing works

Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer

Khan, S. A., Idrees, K., Forslund, A., Zeng, Z., Rosenberg, S. M., Pinças, H., Barany, F., Offit, K., LaQuaglia, M. P., & Paty, P. B. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.20996 · Cited by 9 · see citing works

MDM2, MDMX and p53 in oncogenesis and cancer therapy

Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · see citing works

Advances in sarcoma genomics and new therapeutic targets

Taylor, B. S., Barretina, J. G., Maki, R. G., Antonescu, C. R., Singer, S., & Ladanyi, M. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3087 · Cited by 428 · see citing works

The Roles of MDM2 and MDMX in Cancer

Karni-Schmidt, O., Lokshin, M., & Prives, C. L. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 294 · see citing works

The Role of MDM2 Amplification and Overexpression in Tumorigenesis

Oliner, J. D., Saiki, A. Y., & Caenepeel, S. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026336 · Cited by 246 · see citing works

Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy

Li, Q., & Lozano, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0053 · Cited by 191 · see citing works

Limiting the power of p53 through the ubiquitin proteasome pathwayPreprint

Pant, V., & Lozano, G. (2014) · Genes & Development · doi:10.1101/gad.247452.114 · Cited by 165 · see citing works

hnRNP K is a haploinsufficient tumor suppressor that regulates proliferation and differentiation programs in hematologic malignancies

Gallardo, M., Lee, H. J., Zhang, X., Bueso-Ramos, C., Pageon, L. R., McArthur, M., Multani, A., Nazha, A., Manshouri, T., Parker-Thornburg, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.001 · Cited by 145 · see citing works

The importance of p53 pathway genetics in inherited and somatic cancer genomes

Stracquadanio, G., Wang, X., Wallace, M. D., Grawenda, A. M., Zhang, P., Hewitt, J., Zerón-Medina-Cuairán, J., Castro-Giner, F., Tomlinson, I. P. M., Goding, C. R., et al. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.15 · Cited by 141 · see citing works

GLAD4U: deriving and prioritizing gene lists from PubMed literature

Jourquin, J., Duncan, D. T., Shi, Z., & Zhang, B. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-s8-s20 · Cited by 137 · see citing works

Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability

Pant, V., Xiong, S., Iwakuma, T., Quintás-Cardama, A., & Lozano, G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102241108 · Cited by 134 · see citing works

The roles and regulation of MDM2 and MDMX: it is not just about p53Preprint

Klein, A. M., de Queiroz, R. M., Venkatesh, D., & Prives, C. L. (2021) · Genes & Development · doi:10.1101/gad.347872.120 · Cited by 132 · see citing works

The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans

Pant, V., Quintás-Cardama, A., & Lozano, G. (2012) · Blood · doi:10.1182/blood-2012-05-356014 · Cited by 129 · see citing works

Attenuating the p53 Pathway in Human Cancers: Many Means to the Same EndPreprint

Wasylishen, A. R., & Lozano, G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026211 · Cited by 128 · see citing works

Leveraging Cross-Species Transcription Factor Binding Site Patterns: From Diabetes Risk Loci to Disease Mechanisms

Claussnitzer, M., Dankel, S. N., Klocke, B., Grallert, H., Glunk, V., Berulava, T., Lee, H., Oskolkov, N., Fadista, J., Ehlers, K., et al. (2014) · Cell · doi:10.1016/j.cell.2013.10.058 · Cited by 126 · see citing works

Multiple Stress Signals Activate Mutant p53 In Vivo

Suh, Y., Post, S. M., Elizondo-Fraire, A. C., Macció, D. R., Jackson, J. G., El‐Naggar, A. K., Pelt, C. V., Terzian, T., & Lozano, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0459 · Cited by 119 · see citing works

A Polymorphic p53 Response Element in KIT Ligand Influences Cancer Risk and Has Undergone Natural Selection

Zeron-Medina, J., Wang, X., Repapi, E., Campbell, M. R., Su, D., Castro-Giner, F., Davies, B., Peterse, E. F. P., Sacilotto, N., Walker, G. J., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.017 · Cited by 118 · see citing works

The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians

Knappskog, S., Bjørnslett, M., Myklebust, L. M., Huijts, P. E. A., Vreeswijk, M. P. G., Edvardsen, H., Guo, Y., Zhang, X., Yang, M., Ylisaukko‐oja, S. K., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.019 · Cited by 118 · see citing works

Multi-species, multi-transcription factor binding highlights conserved control of tissue-specific biological pathways

Ballester, B., Medina-Rivera, A., Schmidt, D., Gonzàlez-Porta, M., Carlucci, M., Chen, X., Chessman, K., Faure, A. J., Funnell, A. P., Goncalves, A., et al. (2014) · eLife · doi:10.7554/elife.02626 · Cited by 96 · see citing works

p53/MDM2 signaling pathway in aging, senescence and tumorigenesis

Huang, Y., Che, X., Wang, P., & Qu, X. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.05.001 · Cited by 92 · see citing works

The Regulation of Aging and Longevity: A New and Complex Role of p53

Feng, Z., Lin, M., & Wu, R. (2011) · Genes & Cancer · doi:10.1177/1947601911410223 · Cited by 87 · see citing works

The p53–Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevityPreprint

Pant, V., Xiong, S., Jackson, J. G., Post, S. M., Abbas, H. A., Quintás‐Cardama, A., Hamir, A. N., & Lozano, G. (2013) · Genes & Development · doi:10.1101/gad.227249.113 · Cited by 83 · see citing works

The Mdm network and its regulation of p53 activities: a rheostat of cancer risk

Eischen, C. M., & Lozano, G. (2014) · Human Mutation · doi:10.1002/humu.22524 · Cited by 79 · see citing works

Translational approaches targeting the p53 pathway for anti‐cancer therapy

Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77 · see citing works

Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases

Zhang, Y., Xiong, S., Liu, B., Pant, V., Celii, F. G., Chau, G. P., Elizondo-Fraire, A. C., Yang, P., You, M. J., El‐Naggar, A. K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06146-9 · Cited by 71 · see citing works

Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes

Musa, J., Cidre‐Aranaz, F., Aynaud, M.-M., Orth, M. F., Knott, M. M. L., Mirabeau, O., Mazor, G., Varon, M., Hölting, T. L. B., Grossetête, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12071-2 · Cited by 70 · see citing works

Genetic Modifiers of the p53 PathwayPreprint

Basu, S., & Murphy, M. E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026302 · Cited by 70 · see citing works

Dysregulation of ubiquitin ligases in cancer

Qi, J., & Ronai, Z. A. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.09.001 · Cited by 69 · see citing works

It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy

Kung, C.-P., & Weber, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818744 · Cited by 68 · see citing works

The Many Faces of MDM2 Binding Partners

Riley, M. F., & Lozano, G. (2012) · Genes & Cancer · doi:10.1177/1947601912455322 · Cited by 64 · see citing works

Spontaneous and inherited TP53 genetic alterations

Levine, A. J. (2021) · Oncogene · doi:10.1038/s41388-021-01991-3 · Cited by 62 · see citing works

Common genetic variants in the TP53 pathway and their impact on cancer

Barnoud, T., Parris, J. L. D., & Murphy, M. E. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz052 · Cited by 60 · see citing works

Modulation of the Activity of Sp Transcription Factors by Mithramycin Analogues as a New Strategy for Treatment of Metastatic Prostate Cancer

Malek, A. V., Núñez, L. E., Magistri, M., Brambilla, L., Jovic, S., Carbone, G. M., Morís, F., & Catapano, C. V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035130 · Cited by 59 · see citing works

microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis

Zhang, C., Liu, J., Tan, C., Yue, X., Zhao, Y., Peng, J., Wang, X., Laddha, S. V., Chan, C. S., Zheng, S. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7088 · Cited by 48 · see citing works

p53 drives a transcriptional program that elicits a non-cell-autonomous response and alters cell state in vivo

Moyer, S. M., Wasylishen, A. R., Qi, Y., Fowlkes, N. W., Su, X., & Lozano, G. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2008474117 · Cited by 47 · see citing works

Effects of theMDM2promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk

Knappskog, S., & Lønning, P. E. (2011) · Transcription · doi:10.4161/trns.2.5.16813 · Cited by 40 · see citing works

Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck

Yu, H., Huang, Y., Liu, Z., Wang, L., Li, G., Sturgis, E. M., Johnson, D. G., & Wei, Q. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20806 · Cited by 40 · see citing works

Anatomy of Mdm2 and Mdm4 in evolution

Tan, B. X., Liew, H. P., Chua, J. S., Ghadessy, F. J., Tan, Y. S., Lane, D. P., & Coffill, C. R. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx002 · Cited by 40 · see citing works

MDM2promoter SNP285 and SNP309; phylogeny and impact on cancer risk

Knappskog, S., & Lønning, P. E. (2011) · Oncotarget · doi:10.18632/oncotarget.243 · Cited by 39 · see citing works

Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model

Azzam, G. A., Frank, A. K., Hollstein, M., & Murphy, M. E. (2011) · Cell Cycle · doi:10.4161/cc.10.9.15344 · Cited by 39 · see citing works

Dysfunctional telomeres induce p53‐dependent and independent apoptosis to compromise cellular proliferation and inhibit tumor formation

Wang, Y., Wang, X., Flores, E. R., Yu, J., & Chang, S. S. (2016) · Aging Cell · doi:10.1111/acel.12476 · Cited by 36 · see citing works

Molecular cytogenetics: recent developments and applications in cancer

Das, K., & Tan, P. B. O. (2013) · Clinical Genetics · doi:10.1111/cge.12229 · Cited by 34 · see citing works

Ranking insertion, deletion and nonsense mutations based on their effect on genetic information

Zia, A., & Moses, A. M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-299 · Cited by 34 · see citing works

Alleles of Insm1 determine whether RIP1-Tag2 mice produce insulinomas or nonfunctioning pancreatic neuroendocrine tumors

Kobayashi, S., Contractor, T., Vosburgh, E., Du, Y. N., Tang, L. H., Clausen, R., & Harris, C. R. (2019) · Oncogenesis · doi:10.1038/s41389-019-0127-1 · Cited by 33 · see citing works

SMG7 is a critical regulator of p53 stability and function in DNA damage stress response

Luo, H., Cowen, L. E., Yu, G., Jiang, W. G., & Tang, Y. (2016) · Cell Discovery · doi:10.1038/celldisc.2015.42 · Cited by 33 · see citing works

Association of MDM2 and p53 Polymorphisms with the Advancement of Cervical Carcinoma

Singhal, P., Hussain, S., Thakur, N., Batra, S., Salhan, S., Bhambani, S., & Bharadwaj, M. (2012) · DNA and Cell Biology · doi:10.1089/dna.2012.1718 · Cited by 32 · see citing works

The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis

Xiong, S., Pant, V., Zhang, Y., Aryal, N. K., You, M. J., Kusewitt, D. F., & Lozano, G. (2016) · The Journal of Pathology · doi:10.1002/path.4854 · Cited by 32 · see citing works

Endogenous Human MDM2-C Is Highly Expressed in Human Cancers and Functions as a p53-Independent Growth Activator

Okoro, D. R., Arva, N. C., Gao, C., Polotskaia, A., Puente, C., Rosso, M., & Bargonetti, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077643 · Cited by 32 · see citing works

Fuzzy Tandem Repeats Containing p53 Response Elements May Define Species-Specific p53 Target Genes

Simeonova, I., Lejour, V., Bardot, B., Bouarich-Bourimi, R., Morin, A., Fang, M., Charbonnier, L., & Toledo, F. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002731 · Cited by 31 · see citing works

Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants

Dimitrakopoulos, C. M., Vrugt, B., Flury, R., Schraml, P., Knippschild, U., Wild, P. J., Hoerstrup, S. P., Henne‐Bruns, D., Wuerl, P., Graf, R., et al. (2019) · JAMA Surgery · doi:10.1001/jamasurg.2019.0484 · Cited by 30 · see citing works

Igf2 pathway dependency of the Trp53 developmental and tumour phenotypes

Haley, V., Barnes, D., Sandovici, I., Constância, M., Graham, C. F., Pezzella, F., Bühnemann, C., Carter, E. J., & Hassan, A. B. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201101105 · Cited by 30 · see citing works

MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL

Dong, H., Cheng, F., Fan, L., Zhu, D., Wang, D., Zhu, H., Zhuang, Y., Miao, K., Liu, P., Xu, W., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26222 · Cited by 26 · see citing works

Mouse models of sarcomas: critical tools in our understanding of the pathobiology

Post, S. M. (2012) · Clinical Sarcoma Research · doi:10.1186/2045-3329-2-20 · Cited by 26 · see citing works

Using Mouse Models to Explore MDM-p53 Signaling in Development, Cell Growth, and Tumorigenesis

Gannon, H., & Jones, S. N. (2012) · Genes & Cancer · doi:10.1177/1947601912455324 · Cited by 25 · see citing works

Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma?

Wu, C. L., Yang, P., Liu, B., & Tang, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s232464 · Cited by 23 · see citing works

The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review

Jiang, H., Luo, J., & Lei, H. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2021.108910 · Cited by 23 · see citing works

Discovery of JN122, a Spiroindoline-Containing Molecule that Inhibits MDM2/p53 Protein–Protein Interaction and Exerts Robust In Vivo Antitumor Efficacy

Cheng, J., Yan, Z., Jiang, K., Liu, C., Xu, D., Lyu, X., Hu, X., Zhang, S., Zhou, Y., Li, J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01815 · Cited by 22 · see citing works

Single-Nucleotide Polymorphism 309T>G in the MDM2 Promoter Determines Functional Outcome After Stroke

Rodríguez, C., Ramos-Araque, M. E., Domínguez-Martínez, M., Sobrino, T., Sánchez‐Morán, I., Agulla, J., Delgado‐Esteban, M., Sánchez, J. C. G., Bolaños, J. P., Castillo, J., et al. (2018) · Stroke · doi:10.1161/strokeaha.118.022529 · Cited by 22 · see citing works

Distinct downstream targets manifest p53-dependent pathologies in mice

Pant, V., Xiong, S., Chau, G. P., Tsai, K. Y., Shetty, G., & Lozano, G. (2016) · Oncogene · doi:10.1038/onc.2016.111 · Cited by 21 · see citing works

Mouse modelling of the MDM2/MDMX−p53 signalling axis

Tackmann, N. R., & Zhang, Y. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx006 · Cited by 21 · see citing works

Protecting the genome from mdm2 and mdmx

Melo, A. N., & Eischen, C. M. (2012) · Genes &amp; Cancer · doi:10.1177/1947601912454139 · Cited by 20 · see citing works

MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk

Gansmo, L. B., Bjørnslett, M., Halle, M. K., Salvesen, H. B., Romundstad, P., Hveem, K., VATTEN, L. J., Dørum, A., Lønning, P. E., & Knappskog, S. (2017) · BMC Cancer · doi:10.1186/s12885-017-3094-y · Cited by 20 · see citing works

MDM2 binds and inhibits vitamin D receptor

Heyne, K., Heil, T. C., Bette, B., Reichrath, J., & Roemer, K. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1044176 · Cited by 20 · see citing works

Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes

Ortiz, J., Li, Y., Post, S. M., Pant, V., Xiong, S., Larsson, C. A., El‐Naggar, A. K., Johnson, D. G., & Lozano, G. (2017) · Oncogene · doi:10.1038/onc.2017.344 · Cited by 18 · see citing works

Polymorphisms of MDM4 and risk of squamous cell carcinoma of the head and neck

Yu, H., Wang, L., Liu, Z., Wei, S., Li, G., Sturgis, E. M., & Wei, Q. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834632e4 · Cited by 18 · see citing works

Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age

Fontebasso, A. M., Shirinian, M., Khuong-Quang, D.-A., Béchet, D., Gayden, T., Kool, M., Jay, N. D., Jacob, K., Gerges, N., Hutter, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5571 · Cited by 18 · see citing works

Involvement of p53 R72P polymorphism in the association of MDM2-SNP309 with breast cancer

Lee, Y.-J. (2011) · Oncology Reports · doi:10.3892/or.2011.1254 · Cited by 15 · see citing works

Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche

Pantziarka, P. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.541 · Cited by 15 · see citing works

Association of the MDM2 SNP285 and SNP309 Genetic Variants with the Risk, Age at Onset and Prognosis of Breast Cancer in Central European Women: A Hospital-Based Case-Control Study

Miedl, H., Lebhard, J., Ehart, L., & Schreiber, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030509 · Cited by 14 · see citing works

Neuropilin‐1 is up‐regulated by cancer‐associated fibroblast‐secreted IL‐8 and associated with cell proliferation of gallbladder cancer

Chen, C., Zhang, R., Ma, L., Li, Q., Zhao, Y., Zhang, G., Zhang, D., Li, W., Cao, S., Wang, L., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15825 · Cited by 14 · see citing works

Inactive Cas9 blocks vitreous-induced expression of Mdm2 and proliferation and survival of retinal pigment epithelial cells

Chen, N., Hu, Z., Yang, Y., Han, H., & Lei, H. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.107716 · Cited by 14 · see citing works

Menin and p53 have non-synergistic effects on tumorigenesis in mice

Loffler, K. A., Mould, A. W., Waring, P., Hayward, N. K., & Kay, G. F. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-252 · Cited by 13 · see citing works

Association of MDM 2 T 309 G and p53 A rg72 P ro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma

Renouf, D. J., Zhai, R., Sun, B., Xu, W., Cheung, W. Y., Heist, R. S., Kulke, M. H., Cescon, D. W., Asomaning, K., Marshall, A. L., et al. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12286 · Cited by 13 · see citing works

p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL

Lee, H. J., Gallardo, M., Ma, H., Zhang, X., Larsson, C. A., Mejia, A., Hornbaker, M., Qi, Y., Su, X., Pageon, L. R., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.41 · Cited by 13 · see citing works

Associations of MDM2 rs2279744 and TP53 rs1042522 polymorphisms with cervical cancer risk: A meta-analysis and systematic review

Yu, M., Zhang, Q., & Zhao, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.973077 · Cited by 12 · see citing works

Mdm2 and MdmX Involvement in Human Cancer

Berberich, S. J. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_15 · Cited by 12 · see citing works

SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers

Okamoto, K., Tsunematsu, R., Tahira, T., Sonoda, K., Asanoma, K., Yagi, H., Yoneda, T., Hayashi, K., Wake, N., & Kato, K. (2015) · BMC Medical Genetics · doi:10.1186/s12881-015-0216-8 · Cited by 12 · see citing works

Human genetic variation and the risk of hepatocellular carcinoma development

Ezzikouri, S., Benjelloun, S., & Pineau, P. (2013) · Hepatology International · doi:10.1007/s12072-013-9463-y · Cited by 11 · see citing works

MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer

Vivenza, D., Gasco, M., Monteverde, M., Lattanzio, L., Syed, N., Colantonio, I., Denaro, N., Natoli, G., Comino, A., Russi, E. G., et al. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.01.022 · Cited by 11 · see citing works

Impact of the Mdm2SNP309-G allele on a murine model of colorectal cancer

Zhang, X., Pageon, L. R., & Post, S. M. (2014) · Oncogene · doi:10.1038/onc.2014.377 · Cited by 11 · see citing works

The Enigma of p53Preprint

Lozano, G. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031062 · Cited by 11 · see citing works

p53 in the Clinics

Hainaut, P. L., Wiman, K. G., & Olivier, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8 · Cited by 10 · see citing works

TP53 codon 72 Polymorphism and bladder cancer risk: a meta-analysis and emphasis on the role of tumor or smoking status

Zhang, L., Wang, Y., Qin, Z., Li, R., Cong, R., Ji, C., Meng, X., Wang, Y., Xia, J., & Song, N. (2018) · Journal of Cancer · doi:10.7150/jca.26264 · Cited by 10 · see citing works

Genetic and stochastic influences upon tumor formation and tumor types in Li-Fraumeni mouse models

Chan, C. S., Sun, Y., Ke, H., Zhao, Y., Belete, M. K., Zhang, C., Feng, Z., Levine, A. J., & Hu, W. (2020) · Life Science Alliance · doi:10.26508/lsa.202000952 · Cited by 10 · see citing works

A common pathway to cancer: Oncogenic mutations abolish p53 oscillations

Xiong, L., & Garfinkel, A. (2022) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2022.06.002 · Cited by 9 · see citing works

The transcription-independent mitochondrial cell death pathway is defective in non-transformed cells containing the Pro47Ser variant of p53

Budina-Kolomets, A., Barnoud, T., & Murphy, M. E. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1472194 · Cited by 9 · see citing works

NFκB-Mediated Expression of Phosphoinositide 3-Kinase δ Is Critical for Mesenchymal Transition in Retinal Pigment Epithelial Cells

Han, H., Yang, Y., Han, Z., Wang, L., Dong, L., Qi, H., Liu, B., Tian, J., Vanhaesebroeck, B., Kazlauskas, A., et al. (2023) · Cells · doi:10.3390/cells12020207 · Cited by 8 · see citing works

Characterization of cancer-associated missense mutations in MDM2

Chauhan, K. M., Ramakrishnan, G., Kollareddy, M., & Martinez, L. A. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1125986 · Cited by 8 · see citing works

Genetic Polymorphism of MDM2 SNP309 in Patients with Helicobacter Pylori-Associated Gastritis

Tongtawee, T., Dechsukhum, C., Leeanansaksiri, W., Kaewpitoon, S. J., Kaewpitoon, N., Loyd, R. A., Matrakool, L., & Panpimanmas, S. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.16.7049 · Cited by 6 · see citing works

SNPing away at mutant p53 activitiesPreprint

Ortiz, G. J., & Lozano, G. (2018) · Genes & Development · doi:10.1101/gad.312934.118 · Cited by 6 · see citing works

Map Making in the 21st Century: Charting Breast Cancer Susceptibility Pathways in Rodent Models

Blackburn, A. C., & Jerry, D. J. (2011) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-011-9201-9 · Cited by 5 · see citing works

Genetic Variants in the p14ARF/MDM2/TP53 Pathway Are Associated with the Prognosis of Esophageal Squamous Cell Carcinoma Patients Treated with Radical Resection

Li, J., Tang, Y., Huang, L., Yu, Q., Hu, G., & Yuan, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158613 · Cited by 5 · see citing works

Genetically Modified Mouse Models for Sarcoma Research: A Comprehensive Review

Remiszewski, P., Siedlecki, E., Wełniak-Kamińska, M., Mikuła, M., & Czarnecka, A. M. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01717-8 · Cited by 4 · see citing works

From Genome Guardian to Immune Modulator: The Expanding Roles of Tumor Suppressor p53

Wang, W., Liu, J., Feng, Z., & Hu, W. (2025) · Molecular and Cellular Biology · doi:10.1080/10985549.2025.2571187 · Cited by 4 · see citing works

The 40bp Indel Polymorphism rs150550023 in the MDM2 Promoter is Associated with Intriguing Shifts in Gene Expression in the p53-MDM2 Regulatory Hub

Miedl, H., Dietrich, B., Kaserer, K., & Schreiber, M. (2020) · Cancers · doi:10.3390/cancers12113363 · Cited by 4 · see citing works

MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer

Concin, N. (2011) · Oncology Reports · doi:10.3892/or.2011.1560 · Cited by 4 · see citing works

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis

Benner, A., Mansouri, L., Rossi, D., Majid, A., Willander, K., Parker, A. E., Bond, G., Pavlová, Š., Nückel, H., Merkel, O., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.101170 · Cited by 4 · see citing works

The MDM2 Single-Nucleotide Polymorphism T309G Is Associated With the Development of Epimacular Membranes

Jiang, H., Yan, B., Meng, Z., Zhang, L., Lei, H., & Luo, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.841660 · Cited by 3 · see citing works

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Saqués, A. C., Martinez‐Mendez, A., Crown, J. P., & Eustace, A. J. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70157 · Cited by 2 · see citing works

p53 as Batman: Using a Movie Plot to Understand Control of the Cell Cycle

Gadi, N., Foley, S. E., Nowey, M., & Plopper, G. E. (2013) · Science Signaling · doi:10.1126/scisignal.2003535 · Cited by 2 · see citing works

Association ofMDM2 T309G(rs2279744) Polymorphism and Expression Changes With Risk of Prostate Cancer in the Slovak Population

Sivoňová, M. K., Jurečeková, J., Kaplán, P., Híveš, M., Grendár, M., Tomašcová, A., Dusenka, R., Drobková, H., Evin, D., & Kliment, J. (2020) · Anticancer Research · doi:10.21873/anticanres.14646 · Cited by 2 · see citing works

A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans

Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265 · see citing works

Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes

Ortiz, J., Li, Y., Post, S. M., Pant, V., Xiong, S., Larsson, C. A., El‐Naggar, A. K., Johnson, D. G., & Lozano, G. (2017) · Oncogene · doi:10.1038/onc.2017.344 · Cited by 18 · see citing works

Abstract CN02-01: Factors that impinge on the p53 pathway modify cancer risk

Lozano, G. (2013) · Cancer Prevention Research · doi:10.1158/1940-6215.prev-13-cn02-01

Editorial Comment from Dr Shiina to Murine double minute 2 promoter SNP309 polymorphism and prostate cancer risk: A meta‐analysis

Shiina, H. (2012) · International Journal of Urology · doi:10.1111/j.1442-2042.2012.03083.x

MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population

Akkız, H., Sümbül, A. T., Bayram, S., Bekar, A., & Akgöllü, E. (2010) · Cancer Epidemiology · doi:10.1016/j.canep.2010.04.008 · Cited by 28 · see citing works